Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.

The Journal of pathology - 1 Mar 2020

Singh Naveena, Piskorz Anna M, Bosse Tjalling, Jimenez-Linan Mercedes, Rous Brian, Brenton James D, Gilks C Blake, Köbel Martin

Abstract excerpt

TP53 mutations are considered a surrogate biomarker of the serous-like 'copy number high' molecular subtype of endometrial carcinoma (EC). In ovarian carcinoma, p53 immunohistochemistry (IHC) accurately reflects mutational status with almost 100% specificity but its performance in EC has not been established. This study tested whether p53 IHC reliably predicts TP53 mutations identified by next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Carcinoma, Endometrioid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to DNA Mutational Analysis

Share to Endometrial Neoplasms

Share to Immunohistochemistry

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 31829441
DOI: 10.1002/path.5375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.PMID 31829441Read ↗

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Semantic proximity Read ↗

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.Semantic proximity Read ↗

Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.Semantic proximity Read ↗

Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.Semantic proximity Read ↗

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.Semantic proximity Read ↗

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.Semantic proximity Read ↗

Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.Semantic proximity Read ↗

POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.Semantic proximity Read ↗

Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Semantic proximity Read ↗

Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancerSemantic proximity Read ↗

Molecular Characterization of Endometrial Cancer Using a Laboratory-Developed Multi-Gene NGS Panel.Semantic proximity Read ↗

Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are UncommonSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.